Mckesson Corp

• McKesson extended its pharmaceutical distribution contract with CVS Health through June 2032. • Management reaffirmed its fiscal 2027 adjusted earnings outlook and long-term growth targets. • The company reported annual revenue of $403.43B and net profit of $4.76B.

• McKesson agreed to acquire Precision Medicine Group to expand its oncology portfolio. • The company raised its quarterly dividend payout by fifteen percent. • Annual revenue reached $403.43 billion, ranking first in the industry.

• McKesson agreed to acquire Precision Medicine Group for $2.25 billion. • Q1 revenue and earnings exceeded estimates, prompting higher full-year guidance. • Annual revenue reached $403.43B, ranking first in the pharmaceutical industry.

• McKesson exceeded Wall Street estimates and raised full-year earnings guidance. • Strong cash flow drove share repurchases and a dividend increase. • Analysts issued Buy ratings with an average price target of $979.83.

• McKesson shares declined following margin contraction in the U.S. Pharmaceutical segment. • Management maintained full-year earnings guidance, disappointing investors seeking an upward revision. • Regulatory scrutiny regarding drug pricing and reimbursement creates significant uncertainty for the firm.

• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.